TELO — Telomir Pharmaceuticals Cashflow Statement
0.000.00%
- $50.68m
 - $49.93m
 
Annual cashflow statement for Telomir Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st  | 2022 December 31st  | 2023 December 31st  | 2024 December 31st  | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 
| Standards: | USG | USG | USG | USG | 
| Status: | Final | Final | Final | Final | 
| Net Income/Starting Line | -0.138 | -0.854 | -13.1 | -16.5 | 
| Non-Cash Items | — | — | 9.1 | 11.3 | 
| Unusual Items | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | 0.019 | 0.385 | 0.114 | 0.126 | 
| Change in Prepaid Expenses | ||||
| Change in Payable / Accrued Expenses | ||||
| Cash from Operating Activities | -0.119 | -0.469 | -3.86 | -5.07 | 
| Financing Cash Flow Items | 0.119 | 0.47 | -0.31 | -0.535 | 
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | 0.119 | 0.47 | 3.86 | 6.34 | 
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | 0 | 0.001 | -0 | 1.26 |